Welcome to our dedicated page for INOVIO PHARMACEUTICALS SEC filings (Ticker: INO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on INOVIO PHARMACEUTICALS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into INOVIO PHARMACEUTICALS's regulatory disclosures and financial reporting.
Inovio Pharmaceuticals, Inc. filed a shelf registration statement to offer, from time to time, up to $300,000,000 of common stock, preferred stock, debt securities and/or warrants. The prospectus states offerings will be made pursuant to prospectus supplements that will set final terms and methods of sale.
The prospectus highlights Inovio’s lead candidate INO-3107, notes a BLA accepted for review with a PDUFA target date of October 30, 2026, and describes other pipeline collaborations. The company reports its common stock trades on Nasdaq under the symbol "INO" and cites a last reported sale price of $1.19 per share on July 1, 2026.
INOVIO PHARMACEUTICALS director Wendy L. Yarno received new equity awards as part of her non-employee director compensation. On May 20, 2026, she was granted 34,200 restricted stock units and options on 41,800 shares of common stock with a $1.23 exercise price.
The awards were granted under the 2023 Omnibus Incentive Plan. Both the restricted stock units and the stock options vest 100% on May 20, 2027, meaning they become fully earned on that date if service conditions are satisfied.
INOVIO PHARMACEUTICALS, INC. director Jay Shepard received equity awards as part of his non-employee director compensation. He was granted 34,200 restricted stock units, each representing a contingent right to one share of common stock, and 41,800 stock options with a $1.23 exercise price. Both the RSUs and the options were granted under the 2023 Omnibus Incentive Plan and are scheduled to vest 100% on May 20, 2027. These are compensation-related grants, not open-market purchases or sales.
INOVIO PHARMACEUTICALS, INC. director Ann Calby Miller received new equity awards as part of non-employee director compensation. She was granted 34,200 restricted stock units, each representing one future share of common stock, and 41,800 stock options with a $1.23 exercise price.
Both the RSUs and the options vest 100% on May 20, 2027 under the company’s 2023 Omnibus Incentive Plan. The options expire on May 20, 2036. These are compensation-related grants, not open‑market purchases or sales.
INOVIO PHARMACEUTICALS, INC. reported a routine equity compensation grant to director David B. Weiner. He was awarded 34,200 restricted stock units, each representing one share of common stock, and 41,800 common stock options with an exercise price of $1.23 per share. Both the RSUs and the options vest 100% on May 20, 2027, and the options expire on May 20, 2036. These awards were granted under the company’s 2023 Omnibus Incentive Plan pursuant to its non-employee director compensation policy and do not involve any open-market buying or selling of shares.
INOVIO PHARMACEUTICALS, INC. director Lota S. Zoth received new equity awards as part of non-employee director compensation. She was granted 34,200 restricted stock units, each representing one future share of common stock, and 41,800 stock options with a $1.23 exercise price.
Both the RSUs and options were granted under the company’s 2023 Omnibus Incentive Plan and are scheduled to vest 100% on May 20, 2027. These are compensation-related grants rather than open-market share purchases or sales.
INOVIO PHARMACEUTICALS, INC. director Roger D. Dansey received new equity compensation. On May 20, 2026, he was granted 34,200 restricted stock units and 41,800 stock options with a $1.23 exercise price. Both the RSUs and options vest 100% on May 20, 2027 under the 2023 Omnibus Incentive Plan.
INOVIO PHARMACEUTICALS director Simon X. Benito received new equity awards as part of his non-employee director compensation. On May 20, 2026, he was granted 34,200 restricted stock units, each representing one future share of common stock, and 41,800 stock options with a $1.23 exercise price.
Both the RSUs and options were granted under the 2023 Omnibus Incentive Plan and are scheduled to vest 100% on May 20, 2027, subject to applicable plan terms. These are compensation-related awards, not open-market share purchases or sales.
INOVIO PHARMACEUTICALS Chief Scientific Officer Laurent Humeau reported routine equity-compensation activity. On May 20, 2026, 6,027 restricted stock units vested, and 2,163 common shares were withheld at $1.23 per share to cover tax obligations, leaving him with 46,823 common shares held directly. He also received new awards of 27,440 restricted stock units and 34,160 stock options with a $1.73 exercise price, scheduled to vest in equal annual installments from February 26, 2027 through February 26, 2029.